268. Targeting glutamatergic dysregulation in severe treatment-resistant obsessive-compulsive disorder: integrating serotonergic, dopaminergic, and glutamatergic therapies
Abstract Background Obsessive-Compulsive Disorder (OCD) is a chronic and disabling psychiatric condition affecting 2–3% of the population. While selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy (CBT) remain first-line treatments, up to 40% of patients exhibit treatment-resistant OCD (TR-...